The purpose of the present study is to evaluate the safety and exploratory efficacy of the umbilical cord mesenchymal stem cells for patients with ischemic heart diseases.

Inclusion Criteria:

• Clinical diagnosis of Ischemic cardiomyopathy caused by acute occlusion or severe stenosis of anterior descending artery;
• LVEF (left ventricular ejection fraction): 25-45%;
• Age between 18 and 70, borh gender;
• Women of childbearing age agreed to take contraceptive measures during the whole study period;
• No psychiatric illnesses and speaking dysfunction;
• Informed consent.

Exclusion Criteria:

• Structural heart disease, Valvular heart disease, Refractory hypertension(Unstable blood pressure control), LVEF<24%;
• Serious primary diseases of the liver, kidney and hematopoietic system, Abnormal liver function(glutamic-pyruvic transaminase(ALT), glutamic-oxaloacetic transaminase (AST) is 2 times higher than the normal value), creatinine(Cr) is higher than the upper limit of the normal value;
• Patients suffered from severe arrhythmia;
• Patients suffered from stent thrombosis;
• Patients receiving immunosuppressive therapy;
• Patients have tumor or other lethal diseases (expectation of life<6 months);
• Women who plan to be pregnant or are pregnant or nursing;
• Allergic constitution(Allergic to more than two kinds of drugs,food, or pollen);
• Other clinical trial participants within 3 months;
• Investigators judge other conditions not suitable for inclusion.